Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools
- Bild-Infos
- Download
- Ein weiterer Medieninhalt
Ein Dokument
Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools
Enclosed we send you the news of the day about our IZB-Start-up ChromoTek. We would be pleased if you would consider the message in your news coverage. If you have any question please don´t hesitate to ask.
Press release
Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools
Chicago and Munich - October 20, 2020 - Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies. ChromoTek is the market leader in nanobodies - high-performance recombinant reagents used for breakthrough research discoveries. The combined companies will better address the industry's growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.
"Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers," said Dr. Marion Jung, CEO of ChromoTek. "It is exciting to be working together with a company that shares our values in reproducibility and quality for the benefit of research and beyond." Dr. Jason Li, CEO of Proteintech, said, "This new partnership will deliver considerable value to the market. With global manufacturing across three continents, not only will we serve the research market better, but we'll also deeply impact translational science and therapeutic applications."
ChromoTek GmbH is located in the Biotechnology Innovation and Start-up Center in Martinsried near Munich and has become the leading manufacturer of alpaca nanobodies. The biotech start-up had the vision to improve, accelerate and simplify the research of its customers around the world. "I am very proud that Dr. Marion Jung, Managing Director of ChromoTek GmbH, has achieved this goal and will now serve a global market from Bavaria through the cooperation with Proteintech", said Dr. Peter Hanns Zobel, Managing Director of the IZB.
About Proteintech Group
Proteintech, founded in 2002, is a leading manufacturer of antibodies, proteins and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. With over 70,000 publications and confirmed specificity, Proteintech offers antibodies and immunoassays across research areas. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001-2015 accredited. To learn more about Proteintech, please visit www.ptglab.com.
About ChromoTek
ChromoTek is a pioneer in the development and commercialization of innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, Nanobodies consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a unique experience in the development of Nanobodies with desired affinities, specificities, and formats for dedicated applications in biomedical research where other antibody formats fail. As a market and product leader for high performing reagents, we are proud contributing to breakthrough research discoveries around the world. In addition, ChromoTek is a trusted service provider of custom-made Nanobodies for the pharmaceutical industry. Founded in 2008, ChromoTek has offices in Martinsried (Germany) near Munich and Islandia (NY, USA). To learn more about ChromoTek, please visit www.chromotek.com
Press contact ChromoTekProteintech Group, Inc.
Katie Bellows
About the Innovation and Start-up Center Biotechnology (IZB):
The company IZB mbH, founded in 1995, is the operating company of the Innovation and Start-Up Centers for Biotechnology in Planegg-Martinsried and Freising-Weihenstephan, and has developed into one of the top ten renowned biotechnology centers in the world. More than 50 biotech companies with more than 600 employees are currently located on an area covering 26,000 m2. This is where work focuses on developing drugs against the most severe diseases such as cancer, Alzheimer's disease and various autoimmune diseases - and there are already many successes. At the IZB Freising-Weihenstephan - 15 minutes from the airport - scientists are working on developments in the field of life sciences. An essential criterion for the success of the IZBs is the proximity to top research on the Martinsried/Grosshadern Campus. The new infrastructure measures, such as the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the Chemistry College Elhardt, the two kindergartens BioKids and BioKids2, as well as the two restaurants SEVEN AND MORE and Café Freshmaker, have become decisive location factors. Successful companies that have emerged from the IZB include, for example, Medigene AG, Morphosys AG, Micromet GmbH (now Amgen AG), Octopharma GmbH and Corimmun (today Janssen-Cilag). More information atwww.izb-online.de
Press contact IZB:
Susanne Simon, Head of Public Relations
Innovation and Start-ups Center Biotechnology
Am Klopferspitz 19, D-82152 Planegg-Martinsried near Munich
Tel.: +49 (0)89/55 279 48-17, Fax: +49 (0)89/55 279 48-29
E-Mail: simon@izb-online.de
Website: www.izb-online.de
Managing Director: Dr. Peter Hanns Zobel Munich Local Court HRB 111930 The information transmitted is intended only for the person to which it is addressed and may contain confidential and/or privileged material. Any retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer. Thank you!
